Change Makers in Pharma – the eyeforpharma podcast

1-1 with Janssen's Jane Griffiths (Group Chairman EMEA) on cancer research, blood cancer awareness, pricing and affordability in oncology

In our CEO series, we meet with Janssen's Group Chairman to review blood cancer awareness month, discuss how where we are in the cure for cancer and look at how big pharma should help patients manage the disease journey. Ulrich Neumann, US Managing Director, eyeforpharma, speaks with Jane Griffiths, Company Group Chairman of Janssen Europe, Middle East and Africa.

Expert Panel: New Ways to Pay for Pharma Innovation?

While the market becomes increasingly crowded with innovator drugs, pharma is finding it harder to recoup development costs. Join our panel of experts to understand how we should build innovative, cost-effective payment models based on 21st-century definitions of value. With Tamar Thompson, Director Federal Agency Payment (Bristol-Myers Squibb), Jennifer Hinkel, Partner (McGivney Global Advisors), hosted by Ulrich Neumann, US Managing Director, eyeforpharma)

Patient engagement strategies in the digital environment

It's become widely understood that a focus on patient value has become mission critical as we witness the force of consumerization in healthcare. Join us for a wide ranging conversation on the new digital ecosystem and the type of engagement models pharma companies are currently utilizing. Ulrich speaks with Dave Rosner and Mark Lush, two experienced life sciences consultants, both principal's with Deloitte Consulting who have recently co-authored a widely cited whitepaper on the topic (Deloitte Review, Issue 18 via dupress.com).

Rethinking customer engagement in Pharma

How can pharmaceutical companies get to insights-driven customer engagement, that is the subject of today's program. We meet with one of our favorite marketing leaders over in Silicon Valley, Leilani Latimer who leads Global Marketing as Sr. Director for Zephyr Health.

Debating Price vs Value in Oncology

Join us for this critical discussion about exploding cost in cancer care. Ahead of ASCO, we'll address some of the value frameworks and metrics, and what pharma ought to do to provide better evidence for their prices. You'll get to hear a pretty spirited debate debate between Michael Kolodziej, National Medical Director at Aetna, Steven Paulson, CEO and President at Texas Oncology and our good friend Jack Whelan at Cancer Warrior and Patient Leader.